Image For Activity Cover
16 Hour Buprenorphine Course for PAs
Target Audience
Please note that recent legislation has removed the waiver requirement to prescribe buprenorphine.  Please see this statement from SAMHSA:

PCSS believes strongly in the educational value of this buprenorphine training and encourage you to proceed. 
16 hour training course for physician assistants (PAs) who wish to prescribe buprenorphine. This is Part 2 of the 24 hour course. Please visit for Part 1 (8 hour course).

At the conclusion of this activity, learners should be able to:

  • Provide information about the pharmacology and clinical use of buprenorphine
  • Provide information on other approved antagonist and agonist medications to treat opioid use disorder
  • Provide resources needed to set up office-based treatment of opioid use disorder using buprenorphine  
Method of participation in the activity

To be awarded a maximum of 16 AAPA Category 1 CME credits and a Certificate of Completion you must:

  • Review 16 training modules (16 hours) provided in this activity.
  • Earn a passing score of 75% on each of the module’s post-tests.
  • Complete a final evaluation and follow instructions at the end of the course regarding how to retrieve your Certificate of Completion as well as your continuing credit certificate*.

*Credit will not be awarded unless all components of the program are completed. Partial credit will not be awarded.

Availability: On-Demand
Expires on 07/31/2023
Cost: FREE
Credit Offered:
16 PA-CME Credits
16 Attendance Credits
Contains: 16 Courses
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.

Funding for this initiative was made possible (in part) by grant nos. 6H79TI081968 and 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

For Buprenorphine Training Inquiries, email PCSS.


Powered By